No profile data available.
Xenetic Biosciences, Inc. (XBIO) is a healthcare company in the pharmaceutical administration systems industry, based in Framingham, United States, with about 2 full-time employees.
It reported revenue of $2.98 million for fiscal year 2025, up 19.0% from fiscal year 2024, and net income of -$2.68 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $806,923, up 36.0% from a year before. Its market capitalization was $4.99 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
Xenetic Biosciences reported $2.98 million in revenue for fiscal year 2025, up 19.0% from $2.50 million in fiscal year 2024. In Q1 2026 revenue was $806,923.
$4.99 million as of October 9, 2026.
Listed companies of a similar size in the same industry (pharmaceutical administration systems) include Roivant Sciences Ltd. (ROIV), Rani Therapeutics Holdings, Inc. (RANI), Lexaria Bioscience Corp. (LEXX), Skinvisible, Inc. (SKVI).